Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicentre Randomized Double-blind Placebo-controlled Study to Evaluate the Effect on Albuminuria of 6 Months Treatment With Hydroxycarbamide (Siklos®) or a Placebo in Adults With Sickle Cell Disease:

NCT03806452 is registered in ClinicalTrials.gov with Theravia as lead sponsor.

NCT NCT03806452
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03806452 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicentre Randomized Double-blind Placebo-controlled Study to Evaluate the Effect on Albuminuria of 6 Months Treatment With Hydroxycarbamide (Siklos®) or a Placebo in Adults With Sickle Cell Disease:
Lead sponsor
Theravia
Phase
Phase 2
Overall status
Completed
Start date
May 28, 2019
Completion date
May 30, 2024
Enrollment
86 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease